Printer Friendly

ZILA PHARMACEUTICALS, INC., SETS CANADIAN MANUFACTURING AND SALES AGREEMENT FOR ORASCAN

 PHOENIX, April 14 /PRNewswire/ -- Zila Pharmaceuticals, Inc., a division of Zila, Inc. (NASDAQ: ZILA), has entered into a manufacturing and sales agreement with Germiphene Corporation of Brantford, Ontario, for Zila's oral cancer diagnostic aid OraScan.
 Germiphene will produce and package OraScan at its new state-of-the- art facility. Marketing to Canada's dentists and physicians will be handled by Germiphene's professional detailing force and it's sophisticated in-house phone marketing team.
 Zila President Joseph Hines said a special OraScan exhibit booth is being staffed at every important dental and medical convention in Canada. Lecturers at those conferences are already citing OraScan as an important adjunct to routine oral examinations. OraScan advertising will begin this month in the major national and regional journals read by Canada's health professionals. OraScan will be a major focus of attention at the joint convention of the Canadian Dental Association and Ontario Dental Association, April 28 - May 1 in Toronto.
 According to Hines, Zila is working closely with Canada's dental and medical associations, cancer groups, insurers, and anti-tobacco and anti-alcohol abuse organizations to mount an effective public education campaign on oral cancer. "The message is simple," said Hines. "Oral cancer -- when it's detected early -- can be cured. See your dentist or physician for a quick and painless oral cancer checkup."
 Hines added: "In Germiphene Corporation, Zila has found a capable partner with the ideal organization for manufacturing and distributing our product. Germiphene is thoroughly experienced in selling to Canada's dentists, physicians and hospitals." For nearly 40 years, Germiphene has manufactured and distributed quality products for the dental and health care industries. Germiphene serves customers in Canada, and exports to Asia, South America and Australia.
 -0- 4/14/93
 /NOTE: OraScan is a trademark./
 /CONTACT: Joseph Hines of Zila Pharmaceuticals, 602-266-6700/
 (ZILA)


CO: Zila Pharmaceuticals, Inc.; Germiphene Corporation ST: Arizona IN: MTC SU:

DC-TW -- DC004X -- 5555 04/14/93 09:19 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 14, 1993
Words:312
Previous Article:RPM REPORTS RECORD THIRD QUARTER SALES, EARNINGS AND EARNINGS PER SHARE
Next Article:102.7 KIIS-FM AND SEGA PRESENT KIIS & UNITE CHARITY CONCERT REVUE PREMIERING 'KIISVISION' AND SILENT AUCTION TO BENEFIT PEDIATRIC AIDS
Topics:


Related Articles
ZILA TO ACQUIRE NEW TECHNOLOGY
ZILA, INC., POSTS RECORD FOURTH QUARTER SALES; FY 1993 STARTS STRONG
ZILA'S ORASCAN APPLICATION ADVANCES AT FDA
ZILA SIX MONTH SALES AND EARNINGS BREAK RECORDS
ZILA PHARMACEUTICALS, INC., APPROVED TO MARKET ORASCAN IN AUSTRALIA
ORAL-B EXECUTIVE JOINS ZILA PHARMACEUTICALS, INC.
ZILA LICENSES "FORTUNE 500" COMPANY TO MARKET ORASCAN IN EUROPE & AUSTRALIA
ZILA TO OPEN U.S. PRODUCTION FACILITY FOR KEY ORASCAN INGREDIENT
ZILA, INC. REPORTS RECORD REVENUES
Zila Signs Five-Year Contract to Provide OraTest(R) Oral Cancer Detection Product in China.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters